Drugs News and Research

RSS

Study may pave for effective treatments for blood clotting disorders

A key protein that causes the blood to clot is produced by blood vessels in the lungs and not just the liver, according to new research published today in the journal PLoS One, led by scientists at Imperial College London.

11 Feb 2010

Mental health 'bible' starts revamp with new terminology, diagnoses

The Wall Street Journal: "Mental-health experts wrestling with how to fit temper tantrums, hoarding and even Internet addiction into the current understanding of mental illness are proposing changes to the field's primary reference for diagnoses for the first time in 16 years. The draft revisions of the Diagnostic and Statistical Manual of Mental Disorders—the bible for mental health clinicians and researchers—unveiled Wednesday could have effects that ripple through mental health care."

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Cardiology 2010 conference focuses on current treatments for children with heart disease

An international group of over 900 medical experts gathers today to discuss the most current treatments for children with heart disease. Affecting about 8 in every 1,000 children, congenital (present at birth) heart disease is the most common birth defect. In its severe forms, it is also the leading cause of death from birth defects in infants.

10 Feb 2010

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.

10 Feb 2010

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

University of Adelaide researchers in Australia are finding new ways to block the movement of cells in the body which can cause autoimmune diseases and the spread of cancer.

10 Feb 2010

Trimel BioPharma Holdings updates business developments

Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives.

10 Feb 2010

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)—the leading therapy in the psoriasis drug market in 2008—will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

AB SCIEX technology solution implemented for anti-doping enforcement at the 2010 Winter Games

While millions of viewers around the world are watching breathtaking ski jumps, razor-sharp skating moves and other awe-inspiring athletic feats in Vancouver over the next few weeks, the official doping control laboratory of the 2010 Winter Games will be casting an equally intent eye on the athletes who are competing.

10 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

10 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

10 Feb 2010

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.

10 Feb 2010

Researchers find differences in the biology of lung cancer between men and women

An analysis of genetic and clinical data for nearly 800 patients with non-small cell lung cancer has identified differences in genetic characteristics that are associated with age and sex specific patterns of increased or decreased recurrence-free survival, according to a study in the February 10 issue of JAMA.

10 Feb 2010

Enrollment for SCAN Health Plan Arizona exceeds projections in Maricopa County

More than 6,300 Maricopa County residents selected SCAN Health Plan Arizona as their Medicare Advantage Plan (MAPD) for 2010, far exceeding SCAN's enrollment projections. Eligible individuals may continue to join SCAN until March 31, 2010.

10 Feb 2010

QR Pharma commences clinical trial of Posiphen in early stage AD patients

QR Pharma, Inc. , a developer of novel drugs to treat Alzheimer’s disease, announced today that it began a clinical trial of its lead compound, Posiphen, in early stage AD patients.

10 Feb 2010

Drugs News and Research

Study may pave for effective treatments for blood clotting disorders

Mental health 'bible' starts revamp with new terminology, diagnoses

CINJ researchers develop new vaccine strategy for pancreatic cancer

Cardiology 2010 conference focuses on current treatments for children with heart disease

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

Trimel BioPharma Holdings updates business developments

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Top ten myths about sex

Medicinal chemistry paper related to the discovery of CUDC-101 published

AB SCIEX technology solution implemented for anti-doping enforcement at the 2010 Winter Games

Study shows more women die of heart disease each year than men

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

Researchers find differences in the biology of lung cancer between men and women

Enrollment for SCAN Health Plan Arizona exceeds projections in Maricopa County

QR Pharma commences clinical trial of Posiphen in early stage AD patients

Drug Discovery - Second Edition eBook

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News